AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8242282 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of 100 ml 0.9% NaCl
Number of subjects: 66
Study 2939214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice daily)
Number of subjects: 17
Study 2939214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily)
Number of subjects: 17
Study 2939214 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin and Pindolol
Number of subjects: 17
Study 30465360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil alone (2 mg/kg per dose, three times a day)
Number of subjects: 100
Study 30465360 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil plus Bosentan (Sildenafil: 2 mg/kg per dose, three times a day; Bosentan: 1 mg/kg per dose, twice a day)
Number of subjects: 100
Study 27581574 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient adequacy (MMDA) and dietary diversity scores
Number of subjects: 811
Study 27581574 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 'sentinel foods' (iron rich, fortified, animal source, dairy)
Number of subjects: 811
Study 27581574 — intervention group
Group type: EXPERIMENTAL
Intervention: MMDA calcium, iron, zinc, and dietary diversity
Number of subjects: 811
Study 24923683 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid-based therapy
Number of subjects: 2857
Study 24923683 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid-based therapy
Number of subjects: 2857
Study 22070352 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of apple (1-128 g), doubling every 2-3 weeks
Number of subjects: 40
Study 22070352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 20179229 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 90
Study 20179229 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 90
Study 20179229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18194591 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisoprodol 250-mg tablets
Number of subjects: 562
Study 18194591 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 562
Study 15932830 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid bolus of 1,000 mL
Number of subjects: 142
Study 15932830 — intervention group
Group type: COMPARATOR
Intervention: IV fluid bolus of 500 mL
Number of subjects: 142
Study 15932830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral positioning (left and right)
Number of subjects: 142
Study 15932830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration at 10 L/min via nonrebreather face mask
Number of subjects: 142
Study 15932830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration for fetuses with FSpO(2) < 40%
Number of subjects: 142
Study 15932830 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration for fetuses with FSpO(2) ≥ 40%
Number of subjects: 142
Study 12502669 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 40
Study 12109341 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplements (androstenedione, beta-carotene, CoQ10, garlic, soy, vitamin C and E)
Number of subjects: 0
Study 11107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of antiacetylcholine receptor antibodies
Number of subjects: 63
Study 11107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological investigations
Number of subjects: 63
Study 11107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with clinical type of myasthenia
Number of subjects: 63
Study 11107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic value of acetylcholine receptor antibodies measurement
Number of subjects: 63
Study 8750768 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of glipizide given 30 min before glucose ingestion
Number of subjects: 19
Study 8750768 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of glipizide ingested at 120 min during euglycemic insulin clamps
Number of subjects: 19
Study 2406298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 90 mg/day
Number of subjects: 19
Study 2406298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7362734 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg nomifensine
Number of subjects: 6
Study 7362734 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline
Number of subjects: 6
Study 6437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Epostane
Number of subjects: 20
Study 6437877 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Epostane
Number of subjects: 20
Study 6437877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29471206 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (n = 204)
Number of subjects: 409
Study 29471206 — intervention group
Group type: COMPARATOR
Intervention: No music therapy (n = 205)
Number of subjects: 409
Study 27888984 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal home-based psychoeducative intervention
Number of subjects: 66
Study 27888984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 23990230 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Patients
Number of subjects: 70
Study 23990230 — intervention group
Group type: COMPARATOR
Intervention: Control Group (General Population without HF)
Number of subjects: 70
Study 22889444 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated paper
Number of subjects: 0
Study 22889444 — intervention group
Group type: COMPARATOR
Intervention: Disposable underpad
Number of subjects: 0
Study 18768358 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPI(HD))
Number of subjects: 28
Study 18768358 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (FW)
Number of subjects: 28
Study 18768358 — intervention group
Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 28
Study 18207408 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal transsphenoidal surgery
Number of subjects: 78
Study 15672030 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma volume expansion (250 mL hydroxyethyl starch 6% twice daily in 4 hours, and NaCl 0.9% between doses)
Number of subjects: 216
Study 15672030 — intervention group
Group type: COMPARATOR
Intervention: Control group (NaCl 0.9% when necessary with medication)
Number of subjects: 216
Study 14683655 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (7.5 microg, 15 microg, or 30 microg)
Number of subjects: 60
Study 14683655 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (7.5 microg, 15 microg, or 30 microg)
Number of subjects: 60
Study 14683655 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (one dose)
Number of subjects: 60
Study 14683655 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (one dose)
Number of subjects: 60
Study 14683655 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus and subunit vaccines (two doses)
Number of subjects: 60
Study 10953489 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension and paravaginal defect repair
Number of subjects: 16
Study 10953489 — intervention group
Group type: COMPARATOR
Intervention: Vaginal examination
Number of subjects: 16
Study 8666620 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanmore prosthesis
Number of subjects: 413
Study 8666620 — intervention group
Group type: COMPARATOR
Intervention: Charnley prosthesis
Number of subjects: 413
Study 1283117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 23
Study 1283117 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day finasteride
Number of subjects: 23
Study 1283117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2952396 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 50
Study 2952396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31840323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition orientation and a normoproteic, normocaloric nutrition supplement (group 2)
Number of subjects: 38
Study 31840323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition orientation and the nutritional supplement with TGF‐Î²2 (group 3)
Number of subjects: 38
Study 31840323 — intervention group
Group type: COMPARATOR
Intervention: Nutrition orientation only (group 1)
Number of subjects: 38
Study 29931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage (MRJB)
Number of subjects: 80
Study 29931392 — intervention group
Group type: COMPARATOR
Intervention: Non-compressive dressing (NCD)
Number of subjects: 80
Study 26899523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 40
Study 26899523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messages related to diet
Number of subjects: 1109
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messages related to physical activity
Number of subjects: 1109
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages related to meals and providing food to people in need
Number of subjects: 1109
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity messages related to praise dancing
Number of subjects: 1109
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Media types for health messages
Number of subjects: 1109
Study 24195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of health messages
Number of subjects: 1109
Study 22318328 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) combined with 900 mg/m²/day capecitabine
Number of subjects: 31
Study 20484828 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 223
Study 20484828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 223
Study 18302607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I) including stimulus control instructions, sleep restriction therapy, and sleep education and hygiene.
Number of subjects: 72
Study 18302607 — intervention group
Group type: COMPARATOR
Intervention: Component control group receiving sleep education and hygiene only.
Number of subjects: 72
Study 15943846 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg/day for 4 weeks
Number of subjects: 0
Study 15943846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate 15 mg/day for 4 weeks
Number of subjects: 0
Study 15943846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 30 mg/day for 4 weeks (second-step therapy)
Number of subjects: 0
Study 15943846 — intervention group
Group type: COMPARATOR
Intervention: No medication (control for second-step therapy)
Number of subjects: 0
Study 14598618 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (1 microgram/kg)
Number of subjects: 75
Study 14598618 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine (0.7 mg/kg)
Number of subjects: 75
Study 14598618 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 10807895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally processed cereals (active treatment)
Number of subjects: 53
Study 10807895 — intervention group
Group type: COMPARATOR
Intervention: Ordinary cereals (placebo treatment)
Number of subjects: 53
Study 8799657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 636
Study 8799657 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 636
Study 1324557 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM/EE triphasic
Number of subjects: 4234
Study 1324557 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE triphasic
Number of subjects: 4234
Study 6337196 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-component timothy extract
Number of subjects: 40
Study 6337196 — intervention group
Group type: EXPERIMENTAL
Intervention: two-component timothy extract
Number of subjects: 40
Study 28946539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic upper extremity exercise with breathing
Number of subjects: 40
Study 28946539 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercise only (Control)
Number of subjects: 40
Study 27306393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (EPAP)
Number of subjects: 19
Study 27306393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (EPAP) for ≥ 3 h
Number of subjects: 19
Study 27306393 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPAP)
Number of subjects: 19
Study 26150052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 109
Study 21914148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.015 mg/kg (Group S)
Number of subjects: 78
Study 21914148 — intervention group
Group type: COMPARATOR
Intervention: No sedation (Group NS)
Number of subjects: 78
Study 19937027 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin DEB-TACE
Number of subjects: 84
Study 19937027 — intervention group
Group type: COMPARATOR
Intervention: Bland embolization
Number of subjects: 84
Study 18983646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) with semi-automatic border detection
Number of subjects: 45
Study 18983646 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiographic parameters of dyssynchrony
Number of subjects: 45
Study 16857659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate continuously with an addition of 10 mg medroxyprogesterone acetate (MPA) during the last 12 days of the 28‐day cycle
Number of subjects: 106
Study 12823267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of red wine
Number of subjects: 11
Study 12823267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of beer
Number of subjects: 11
Study 12823267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of spirits (Dutch gin)
Number of subjects: 11
Study 12823267 — intervention group
Group type: COMPARATOR
Intervention: Dinner with sparkling mineral water (control)
Number of subjects: 11
Study 10805891 — intervention group
Group type: EXPERIMENTAL
Intervention: Male donor-female recipient transplants
Number of subjects: 40
Study 10805891 — intervention group
Group type: COMPARATOR
Intervention: Sex-matched (male to male) control explants
Number of subjects: 40
Study 10805891 — intervention group
Group type: EXPERIMENTAL
Intervention: Allografts
Number of subjects: 40
Study 9015114 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 bovine rotavirus vaccine
Number of subjects: 0
Study 9015114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine and rhesus rotavirus vaccines (meta-analysis)
Number of subjects: 0
Study 9015114 — intervention group
Group type: COMPARATOR
Intervention: Bovine and rhesus rotavirus vaccines
Number of subjects: 0
Study 2002864 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen
Number of subjects: 93
Study 2002864 — intervention group
Group type: COMPARATOR
Intervention: Histofreezer
Number of subjects: 93
Study 6829497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vindesine (1.2 mg/m2, 5-day infusion, every 3 weeks)
Number of subjects: 33
Study 6829497 — intervention group
Group type: COMPARATOR
Intervention: Continuous vinblastine (1.5 mg/m2/day, every 3 weeks)
Number of subjects: 33
Study 30856418 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex language (passive voice)
Number of subjects: 42
Study 30856418 — intervention group
Group type: COMPARATOR
Intervention: Simpler language (active voice)
Number of subjects: 42
Study 29436854 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mother's voice exposure
Number of subjects: 0
Study 29436854 — intervention group
Group type: COMPARATOR
Intervention: Passive mother's voice exposure
Number of subjects: 0
Study 29436854 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with brain injury
Number of subjects: 0
Study 25449552 — intervention group
Group type: EXPERIMENTAL
Intervention: BRO HIV/STI risk‐reduction intervention
Number of subjects: 595
Study 25449552 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 595
Study 23319285 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic (SIL) right colectomy
Number of subjects: 159
Study 23319285 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL) right colectomy
Number of subjects: 159
Study 21114656 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept‐mycophenolate mofetil (MMF)
Number of subjects: 89
Study 21114656 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept‐sirolimus (SRL)
Number of subjects: 89
Study 21114656 — intervention group
Group type: COMPARATOR
Intervention: TAC‐MMF
Number of subjects: 89
Study 19861106 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of clowns during surgery
Number of subjects: 61
Study 19861106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clowns)
Number of subjects: 61
Study 17827354 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 99
Study 17827354 — intervention group
Group type: COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP)
Number of subjects: 99
Study 15598790 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of alcohol daily (two drinks)
Number of subjects: 31
Study 15598790 — intervention group
Group type: COMPARATOR
Intervention: 0 g of alcohol (control)
Number of subjects: 31
Study 11829198 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN ointment (13.4 +/- 3.61 mg ISDN)
Number of subjects: 12
Study 11829198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9780281 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF alone
Number of subjects: 30
Study 9780281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both G‐CSF and rifabutin
Number of subjects: 30
Study 9780281 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin alone
Number of subjects: 30
Study 8537705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg orally
Number of subjects: 53
Study 8537705 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin therapy
Number of subjects: 53
Study 2320489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponging plus acetaminophen
Number of subjects: 73
Study 2320489 — intervention group
Group type: COMPARATOR
Intervention: Sponging alone
Number of subjects: 73
Study 2320489 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 73
Study 656286 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin solution alone
Number of subjects: 8
Study 656286 — intervention group
Group type: EXPERIMENTAL
Intervention: Three intact capsules containing digoxin solution
Number of subjects: 8
Study 656286 — intervention group
Group type: EXPERIMENTAL
Intervention: Three capsules containing digoxin solution sectioned in half
Number of subjects: 8
Study 656286 — intervention group
Group type: EXPERIMENTAL
Intervention: Three capsules containing digoxin solution dissolved in water prior to administration
Number of subjects: 8
Study 31666651 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy (ABCT)
Number of subjects: 34
Study 31666651 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 34
Study 26703291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK (Visx Star S4 Customvue)
Number of subjects: 108
Study 26703291 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized PRK (Allegretto Wave Eye-Q 400 Hz)
Number of subjects: 108
Study 26703291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK
Number of subjects: 108
Study 26703291 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized PRK
Number of subjects: 108
Study 24293605 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible casts that can be removed at home
Number of subjects: 317
Study 24293605 — intervention group
Group type: COMPARATOR
Intervention: Traditional management using a cast conventionally removed in hospital
Number of subjects: 317
Study 20927574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Toolkit distributed via direct mail)
Number of subjects: 209
Study 20927574 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 209
Study 19568027 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of high-dose intravenous therapy followed by 3 weeks of oral therapy
Number of subjects: 70
Study 19568027 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days or less intravenous treatment
Number of subjects: 70
Study 19568027 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature and C-reactive protein monitoring
Number of subjects: 70
Study 19568027 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened course of intravenous and oral antibiotic therapy
Number of subjects: 70
Study 16766444 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper names with distractors (associate condition)
Number of subjects: 0
Study 16766444 — intervention group
Group type: EXPERIMENTAL
Intervention: Common names with distractors
Number of subjects: 0
Study 16766444 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper names with distractors (identical condition)
Number of subjects: 0
Study 16766444 — intervention group
Group type: COMPARATOR
Intervention: Distractors belonging to a different professional category (different condition)
Number of subjects: 0
Study 14722627 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (1000 mg/day for 12 weeks)
Number of subjects: 40
Study 14722627 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (1000 mg/day for 12 weeks)
Number of subjects: 40
Study 11218025 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc degeneration classified from MR images
Number of subjects: 43